Telix Pharmaceuticals Ltd (NASDAQ:TLX)
| Market Cap | $2.84B-4.6% |
| Revenue (ttm) | $890.79M |
| Net Income | $33.50M |
| EPS | $0.10 |
| Shares Out | 339.78M |
| PE Ratio | 83.70 |
| Forward PE | -313.37 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 269,432 |
| Open | $8.66 |
| Previous Close | $8.71 |
| Day's Range | $8.37 - $8.70 |
| 52-Week Range | $6.28 - $13.11 |
| Beta | 0.63 |
| Analysts | none |
| Price Target | $19.37(+131.37%) |
| Earnings Date | n/a |
About TLX
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Telix Pharmaceuticals Ltd Stock Analysis — InsiderScore
Telix Pharmaceuticals Ltd scored higher than 21% of companies evaluated by InsiderBuying, and ranked 71st out of 110 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Telix Pharmaceuticals Ltd bought $20.0K of stock across 1 purchase in the last 90 days, the largest of them $20.0K.
The average purchase added about 17% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
2 firms rating TLX in the last 3 months, one vote each. Issuer-paid research is not counted.
$TLX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in TLX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by TLX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
TLX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New TLX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to TLX from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from TLX’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
+10.1 since Sep 24Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
